Editas Medicine (NASDAQ:EDIT – Get Free Report) and ImmunityBio (NASDAQ:IBRX – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.
Earnings & Valuation
This table compares Editas Medicine and ImmunityBio”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Editas Medicine | $40.52 million | 10.23 | -$160.06 million | ($0.75) | -3.60 |
| ImmunityBio | $165.79 million | 50.57 | -$351.40 million | ($0.97) | -8.15 |
Analyst Ratings
This is a breakdown of recent ratings for Editas Medicine and ImmunityBio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Editas Medicine | 1 | 0 | 4 | 0 | 2.60 |
| ImmunityBio | 1 | 0 | 6 | 0 | 2.71 |
Editas Medicine presently has a consensus price target of $6.00, indicating a potential upside of 122.22%. ImmunityBio has a consensus price target of $14.20, indicating a potential upside of 79.52%. Given Editas Medicine’s higher probable upside, research analysts plainly believe Editas Medicine is more favorable than ImmunityBio.
Profitability
This table compares Editas Medicine and ImmunityBio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Editas Medicine | -157.32% | -196.63% | -38.17% |
| ImmunityBio | -598.55% | N/A | -51.65% |
Institutional and Insider Ownership
71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by company insiders. Comparatively, 66.1% of ImmunityBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
Editas Medicine has a beta of 2.09, meaning that its stock price is 109% more volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500.
Summary
Editas Medicine beats ImmunityBio on 8 of the 14 factors compared between the two stocks.
About Editas Medicine
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
About ImmunityBio
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
